Evofem Biosciences Inc

NASDAQ:EVFM  
2.22
+0.02 (+0.91%)
4:27:35 PM EDT: $2.22 0.00 (0.00%)
Earnings Announcements

Evofem Biosciences Reports Q3 Loss Per Share $0.37

Published: 11/09/2020 21:59 GMT
Evofem Biosciences Inc (EVFM) - Evofem Biosciences Reports Third Quarter 2020 Financial Results and Provides Corporate Update.
Q3 Loss per Share $0.37.
Q3 Earnings per Share Estimate $-0.44 -- Refinitiv Ibes Data (analyst estimates).
Secured $25 Million Strategic Investment From Adjuvant Capital.
Initiated Pivotal Phase 3 Evoguard Trial of Evo100 for Prevention of Chlamydia and Gonorrhea.
Unrestricted Cash and Short-term Investments Were $86.7 Million at September 30, Compared to $23.8 Million at December 31, 2019.
Revenue is expected to be $6.4 Million
Adjusted EPS is expected to be -$0.33

Next Quarter Revenue Guidance is expected to be $11.15 Million
Next Quarter EPS Guidance is expected to be -$0.35

More details on our Analysts Page.